Universal donor derived CD33 CAR-NK cell therapy (Nationwide Children'S Hospital)

N/A

Report date: 2026/04/03 20:03:44

Base Information

Drug NameUniversal donor derived CD33 CAR-NK cell therapy (Nationwide Children'S Hospital)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Cytokine-induced killer cell > Chimeric antigen receptor CIK cell therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV6 vector
Mechanisms of ActionNatural killer cell replacementsMyeloid cell surface antigen CD33 modulators
TargetsMyeloid cell surface antigen CD33
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNationwide Children'S Hospital
China Registration ClassN/A

Develop Information

Active CompaniesNationwide Children'S Hospital
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A